trial
as of 2026-07-01A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
NCTId NCT00538070
at a glance
— · Completed
Enrollment 68 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2012-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
68 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2007-08
Primary completion
2012-07
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Massachusetts General HospitalLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator
Investigators
2
A. Eden Evins, M.D., M.P.H.Principal Investigator
Marc L. Steinberg, PH.D.Principal Investigator
Sites
2 total
Belmont, United StatesBoston, United States
Facts & assertions
4 sourced
Enrollment
68
Phase
NA
Primary Completion Date
2012-07
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
indication
indication
investigator